The University of New Mexico

Other

Pamela Hall

Jacob C Greenberg

Bryce Chackerian

Snezna Rogelj

Eric R Prossnitz

David S Peabody

Charles Melancon

Yasushi Ogasawara

Kathleen Triplett

Helen J Hathaway

Seth Michael Daly

Bradley Owen Elmore

The present invention is directed to virus-like particles (VLPs) which are engineered to present epitopes from(SA), preferably autoinducing peptides (AIPs) which regulate quorum-sensing dependent virulence in this pathogen, or epitopes from SA toxins and leukocidins. These VLPs may be used to provide immunogenic compositions and efficacious vaccines. In a mouse model of SA dermonecrosis, vaccination with AIP-containing VLPs or SA toxin-containing VLPs induces protective immunity to limit the pathogenesis of SA infection and promote bacterial clearance.

VLP-based vaccines for targetingsecreted virulence factors

The present invention is directed to the use of compounds which are modulators of the G protein-Coupled Estrogen Receptor (GPER) for the inhibition &#x2014;and/or treatment of Bacterial infections, especially including metMctHin-resistant(MRSA) infections. Pharmaceutical compositions and methods of treatment of bacterial pathogens, including MRSA are also described.

Inhibition and treatment of bacterial infections by sex-specific GPER targeting

In one aspect, this disclosure describes a pharmaceutical composition that generally includes frankiamicin A and a pharmaceutically acceptable carrier. In another aspect, this disclosure describes a method of treating a subject having, or at risk of having, a condition caused by a microbial infection treatable with frankiamicin A. Generally, the method includes administering to the subject an amount of frankiamicin A effective to ameliorate at least one symptom or clinical sign of the condition.

Frankiamicin A compositions and methods

Growing community of inventors

Albuquerque, NM, United States of America

Pamela Hall